Design principles for therapeutic angiogenic materials

被引:137
作者
Briquez, Priscilla S. [1 ,2 ]
Clegg, Lindsay E. [3 ,4 ]
Martino, Mikal M. [5 ]
Mac Gabhann, Feilim [3 ,4 ,6 ]
Hubbell, Jeffrey A. [1 ,2 ,7 ]
机构
[1] Ecole Polytech Fed Lausanne, Sch Life Sci, Inst Bioengn, CH-1015 Lausanne, Switzerland
[2] Ecole Polytech Fed Lausanne, Sch Engn, CH-1015 Lausanne, Switzerland
[3] Johns Hopkins Univ, Inst Computat Med, Baltimore, MD 21218 USA
[4] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21218 USA
[5] Osaka Univ, World Premier Int Immunol Frontier Res Ctr, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan
[6] Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA
[7] Univ Chicago, Inst Mol Engn, 5640 South Ellis Ave, Chicago, IL 60637 USA
关键词
FIBROBLAST-GROWTH-FACTOR; HEPARAN-SULFATE PROTEOGLYCANS; BLOOD-VESSEL FORMATION; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; INJECTABLE HYDROGELS; SUSTAINED DELIVERY; FACTOR-BINDING; IN-VIVO; VEGF-A;
D O I
10.1038/natrevmats.2015.6
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Despite extensive research, pro-angiogenic drugs have failed to translate clinically, and therapeutic angiogenesis, which has potential in the treatment of various cardiovascular diseases, remains a major challenge. Physiologically, angiogenesis - the process of blood-vessel growth from existing vasculature - is regulated by a complex interplay of biophysical and biochemical cues from the extracellular matrix (ECM), angiogenic factors and multiple cell types. The ECM can be regarded as the natural 3D material that regulates angiogenesis. Here, we leverage knowledge of ECM properties to derive design rules for engineering pro-angiogenic materials. We propose that pro-angiogenic materials should be biomimetic, incorporate angiogenic factors and mimic cooperative interactions between growth factors and the ECM. We highlight examples of material designs that demonstrate these principles and considerations for designing better angiogenic materials.
引用
收藏
页数:15
相关论文
共 177 条
[1]   Analysis of mural cell recruitment to tumor vessels [J].
Abramsson, A ;
Berlin, Ö ;
Papayan, H ;
Paulin, D ;
Shani, M ;
Betsholtz, C .
CIRCULATION, 2002, 105 (01) :112-117
[2]   VEGF internalization is not required for VEGFR-2 phosphorylation in bioengineered surfaces with covalently linked VEGF [J].
Anderson, Sean M. ;
Shergill, Bhupinder ;
Barry, Zachary T. ;
Manousiouthakis, Eleana ;
Chen, Tom T. ;
Botvinick, Elliot ;
Platt, Manu O. ;
Iruela-Arispe, M. Luisa ;
Segura, Tatiana .
INTEGRATIVE BIOLOGY, 2011, 3 (09) :887-896
[3]   Role of platelet-derived growth factors in physiology and medicine [J].
Andrae, Johanna ;
Gallini, Radiosa ;
Betsholtz, Christer .
GENES & DEVELOPMENT, 2008, 22 (10) :1276-1312
[4]   Endothelial/pericyte interactions [J].
Armulik, A ;
Abramsson, A ;
Betsholtz, C .
CIRCULATION RESEARCH, 2005, 97 (06) :512-523
[5]   Extracellular matrix, inflammation, and the angiogenic response [J].
Arroyo, Alicia G. ;
Iruela-Arispe, M. Luisa .
CARDIOVASCULAR RESEARCH, 2010, 86 (02) :226-235
[6]   Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system [J].
Augustin, Hellmut G. ;
Koh, Gou Young ;
Thurston, Gavin ;
Alitalo, Kari .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2009, 10 (03) :165-177
[7]   Sequential delivery of angiogenic growth factors improves revascularization and heart function after myocardial infarction [J].
Awada, Hassan K. ;
Johnson, Noah R. ;
Wang, Yadong .
JOURNAL OF CONTROLLED RELEASE, 2015, 207 :7-17
[9]   Neuropilin-1 promotes VEGFR-2 trafficking through Rab11 vesicles thereby specifying signal output [J].
Ballmer-Hofer, Kurt ;
Andersson, Anneli E. ;
Ratcliffe, Laura E. ;
Berger, Philipp .
BLOOD, 2011, 118 (03) :816-826
[10]   Arteriolization of capillaries and FGF-2 upregulation in skeletal muscles of patients with chronic peripheral arterial disease [J].
Baum, O ;
Djonov, V ;
Ganster, M ;
Widmer, M ;
Baumgartner, I .
MICROCIRCULATION, 2005, 12 (06) :527-537